Elixa MediScience

Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis.

The company's approach targets multiple pathophysiological mechanisms simultaneously, addressing the limitations of existing single-pathway strategies.

Elixa operates as a virtual biotech, outsourcing all R&D activity, with a strategy of advancing lead candidates to first-in-human readiness before seeking development and commercialisation partners.